{
    "2018-04-08": [
        [
            {
                "time": "",
                "original_text": "A股独角兽全速赶来 发行高市盈率恐惧症再现？",
                "features": {
                    "keywords": [
                        "A股",
                        "独角兽",
                        "高市盈率",
                        "恐惧症"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "长江证券：从药明康德过会看CRO行业机遇",
                "features": {
                    "keywords": [
                        "长江证券",
                        "药明康德",
                        "CRO",
                        "行业机遇"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2018年全球CRO公司TOP10排名，药明康德升至第9",
                "features": {
                    "keywords": [
                        "2018年",
                        "全球CRO",
                        "药明康德",
                        "排名",
                        "第9"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "药明康德50天“插队”过会 “一拆三”开启A股回归路",
                "features": {
                    "keywords": [
                        "药明康德",
                        "50天",
                        "插队",
                        "过会",
                        "一拆三",
                        "A股回归"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物板块涨幅亮眼 已不仅是资金避险逻辑",
                "features": {
                    "keywords": [
                        "医药生物",
                        "板块涨幅",
                        "资金避险"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]医药生物行业简评：仿制药产业沐春风 开启强国之路",
                "features": {
                    "keywords": [
                        "买入评级",
                        "医药生物",
                        "仿制药",
                        "强国之路"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}